Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 98 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tdap Clear all
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06736041
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, RotaTeq, Vaxelis vaccine, Varivax, Hexaxim Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
1,714 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
66
States / cities
Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 2, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Intervention Promoting HPV Vaccination in Safety-net Clinics

NCT01729429
View directory record Official record
Conditions
Human Papilloma Virus-Related Cervical Carcinoma
Interventions
HPV brochure, recall, reminders, General Adolescent Vaccine Brochure
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
11 Years to 18 Years · Female only
Enrollment
831 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 2, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

NCT02199691
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed, GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
1,715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Downey, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 2, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment, Feedback, Incentive, Exchange (AFIX OB) A Customizable Quality Improvement Intervention to Increase Maternal Vaccine Uptake

NCT04678271
View directory record Official record
Conditions
Influenza, Whooping Cough
Interventions
AFIX-OB Quality Improvement Package
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 2, 2026, 2:53 AM EDT
Completed Phase 1 Interventional

Teen Depression Awareness Project (TDAP)

NCT00099827
View directory record Official record
Conditions
Depression
Interventions
Education
Behavioral
Lead sponsor
RAND
Other
Eligibility
13 Years to 17 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
8
States / cities
Los Angeles, California • San Fernando, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Sep 2, 2026, 2:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine

NCT00347958
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Tetanus-diphtheria-acellular pertussis (Tdap) vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
15 Years to 69 Years
Enrollment
545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
4
States / cities
Jonesboro, Arkansas • Bossier City, Louisiana • University Heights, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Sep 2, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety

NCT00263692
View directory record Official record
Conditions
Diphtheria, Acellular Pertussis, Tetanus
Interventions
Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
15
States / cities
Jonesboro, Arkansas • Fountain Valley, California • Oakland, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 2, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS

NCT04071158
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSV Vaccine, Tdap, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
713 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
16
States / cities
Stockbridge, Georgia • Honolulu, Hawaii • Wichita, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2021 · Synced Sep 2, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

NCT00385255
View directory record Official record
Conditions
Acellular Pertussis, Diphtheria, Tetanus
Interventions
Fluarix®, Boostrix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years and older
Enrollment
1,726 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
12
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 2, 2026, 2:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The Safety of Boostrix Following Routine Immunization of Pregnant Women

NCT03463577
View directory record Official record
Conditions
Whooping Cough
Interventions
Safety assessment following routine immunization with Boostrix
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Female only
Enrollment
65,783 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Sep 2, 2026, 2:53 AM EDT
Completed Phase 2 Interventional

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

NCT06015308
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Tdap vaccine, PPS vaccine
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 2, 2026, 2:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

SC2i VIPER: EnVenomation Investigation Pilot to Evaluate Recovery

NCT03170297
View directory record Official record
Conditions
Critical Illness
Interventions
Research interventions of blood sampling and data collection
Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 2, 2026, 2:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Adacel® Vaccine Administered to Persons 10 Years of Age

NCT01311557
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed
Biological
Lead sponsor
Sanofi
Industry
Eligibility
10 Years to 11 Years
Enrollment
1,302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
34
States / cities
Chandler, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 2, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

NCT05705440
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 vaccine, Control
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years to 49 Years · Female only
Enrollment
3,855 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
27
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 2, 2026, 2:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

TDAP Safety in Pregnant Women

NCT02209623
View directory record Official record
Conditions
Pertussis
Interventions
TDAP
Biological
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Durham, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Sep 2, 2026, 2:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine

NCT00777257
View directory record Official record
Conditions
Meningitis, Meningococcemia, Pertussis, Tetanus, Diphtheria
Interventions
T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
11 Years to 17 Years
Enrollment
1,345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
20
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Boulder, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 2, 2026, 2:53 AM EDT
Recruiting Phase 2 Interventional

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

NCT06639074
View directory record Official record
Conditions
Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Ovarian Carcinosarcoma, Advanced Ovarian Clear Cell Adenocarcinoma, Advanced Ovarian Endometrioid Adenocarcinoma, Advanced Ovarian High Grade Serous Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Primary Peritoneal High Grade Serous Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Mixed Cell Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Leukapheresis, Magnetic Resonance Imaging, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine, Placebo Administration, Tetanus and Diphtheria Toxoids Adsorbed
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 2, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adapting Motivational Interviewing for Maternal Immunizations (MI4MI)

NCT04302675
View directory record Official record
Conditions
Maternal Immunization
Interventions
Prevention, Maternal Immunization
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
15 Years and older · Female only
Enrollment
1,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Sep 2, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vaccine Acceptance in Pregnant Minority Women

NCT01740310
View directory record Official record
Conditions
Pregnancy
Interventions
Maternal Vaccine Education
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia • Riverdale, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Sep 2, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults

NCT02261961
View directory record Official record
Conditions
Sarcopenia, Aging, Immune Function
Interventions
TDAP, Acute Resistance Exercise, Resistance Exercise Training, Post-training Follow-up, Nutritional Supplement (Muscle Armor), Placebo (Kool-Aid)
Biological · Other · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
North Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 2, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pentavalent DTaP-Hep B-IPV

NCT00133445
View directory record Official record
Conditions
Diphtheria, Hepatitis B, Poliomyelitis, Pertussis, Tetanus
Interventions
DTaP-Hep B-IPV Vaccine, Monovalent Hep B Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 5 Days
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Sep 2, 2026, 2:53 AM EDT
Active, not recruiting Phase 3 Interventional

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

NCT03650114
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
86
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 2, 2026, 2:53 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines

NCT07493460
View directory record Official record
Conditions
Immunology, Healthy Adults
Interventions
trivalent inactivated influenza vaccine (TIV), nonavalent HPV vaccine (HPV), hepatitis A (HAV) vaccines, tetanus, diphtheria and acellular pertussis vaccine (Tdap)
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 2, 2026, 2:53 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age

NCT07730450
View directory record Official record
Conditions
COVID-19 Vaccines
Interventions
BNT162b2 Vaccine, Tdap Vaccine
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
5
States / cities
Walnut Creek, California • Miami Lakes, Florida • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 2, 2026, 2:53 AM EDT